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probability that the outcome of interest exceeded the threshold. The posterior 
distribution had a 93.0% probability. When data from the ECST study formed the 
prior distribution, the posterior distribution had only a 57.5% probability of 
exceeding the threshold. This reflects a revised prior which included a lower 
(relative to ACAS) expectation of stroke in the AMM population as informed by 
ECST data. CONCLUSIONS: Bayesian analysis allows the incorporation of 
differing prior information, whether representing clinical opinion or clinical 
trials. This permits the observation of how differing priors affect the posterior 
distribution and, hence, interpretations of predicted clinical outcomes between 
treatments.  
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University School of Pharmacy, Denver, CO, USA, 3University of Colorado, Denver, Aurora, CO, USA  
OBJECTIVES: The objective was to identify the optimal statistical method for 
regression analysis of the EQ-5D index. Specifically, we compared the 
performance of alternative regression methods in estimating incremental 
preference-based health related quality of life scores from the EQ-5D index. 
Importance of this work is high as preference-based scores derived from the EQ-
5D index are used to calculate quality-adjusted life years (QALYs), the most 
common measure of health outcomes used in cost-effectiveness analysis. Many 
health utility variables are censored from the top by construction, i.e. full health 
at unity. This is a utility measurement dilemma as 46% of US respondents report 
a perfect EQ-5D score. Also, EQ-5D is treated as a continuous variable; however 
due to its derivation algorithm there is a gap nearly equivalent to one standard 
deviation in the US preference-based scores of the EQ-5D index (no values 
between 0.8603 and 1). METHODS: Simulation analyses were implemented to 
compare the performance of OLS, median regression, Tobit, and robust 
extensions of Tobit models. First, pooled 2000-2003 Medical Expenditure Panel 
Survey data was randomly divided into independent derivation and validation 
sets to estimate the relationship between the EQ-5D index and SF-12 physical 
summary scores. Second, the performance of the same estimation methods was 
compared in a Monte Carlo simulation under ten non-normal distributions. 
RESULTS: Median regression outperformed all other methods in the first 
simulation analysis followed by the re-censored Tobit method. Median 
regression also resulted in the smallest mean squared prediction errors in the 
Monte Carlo simulations, followed by the Tobit method with logistic distribution. 
CONCLUSIONS: Median regression appears to be the most robust method to use 
in regression analysis of the EQ-5D index. If normality and homoscedasticity 
assumptions are not met, then logistic-Tobit regression can be used as a robust 
extension of the classical Tobit method.  
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OBJECTIVES: In 2000, Ontario initiated the world’s first universal influenza 
immunization program (UIIP). Our objective was to simulate the effect of this 
program on influenza attack rates using a new multi-strain dynamic influenza 
model. We compared our model results to a previous study of pre- and post-UIIP 
rates of influenza-associated events in Ontario. METHODS: Our model is age-
stratified, compartmental, and explicitly tracks two A strains (H1N1, H3N2) and 
two B lineages (Victoria, Yamagata). It also incorporates transmission rate 
seasonality, and accounts for non-homogeneous mixing among age groups via a 
contact matrix. U.S. age-stratified average yearly attack rates and the fraction of 
influenza A versus B cases were used as calibration targets. The resulting 
posterior sets of natural history parameters were run together with Ontario 
demographic and vaccine coverage data. RESULTS: Our simulations showed the 
following post-UIIP reduction in yearly attack rate: <5yrs: 48(31-62)%; 5-19yrs: 
49(33-64)%; 20-49yrs: 52(36-66)%; 50-64yrs: 58(42-71)%; 65-74yrs: 59(43-72)%; 75-
84yrs: 58(41-71)%; 85+yrs: 57(40-70)%. We compared our results to Kwong et al. 
(2008, PLoS Med 5(10): e211)’s analysis of post-UIIP reductions in influenza-
associated events, making the assumption that within each age group, event 
rates scale linearly with attack rates. Though qualitatively similar, overall their % 
reductions are at the upper end of our results. CONCLUSIONS: Our model results 
support the conclusion that Ontario’s Universal Influenza Immunization 
Program has brought about a significant reduction in the province’s incidence of 
influenza. Though the relative increase in vaccine uptake due to the UIIP was 
greatest below age 50, reductions in attack rate were greatest in ages 50 and 
over, indicating indirect benefit for the elderly. Reductions inferred by Kwong et 
al. (2008) are on the high side of our results, but this is consistent with their 
assertion that post-UIIP influenza seasons across Canada were intrinsically less 
severe during the study period. 
 
PODIUM SESSION II:  
PATIENT PROTECTION AND AFFORABLE CARE ACT & OTHER HEALTH CARE 
REFORM STUDIES  
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THE IMPACT OF MASSACHUSETTS HEALTH CARE REFORM ON PATIENT 
OUTCOMES  
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OBJECTIVES: Key provisions of the 2006 Massachusetts health care reform and 
national legislation passed in 2010 were individual mandates to obtain health 
insurance. Increasing health insurance coverage is thought to lead to increased 
access to primary/preventive health care and improved patient outcomes. We 
examined the impact of Massachusetts health reform on preventable 
hospitalizations and cancers. METHODS: The Healthcare Cost and Utilization 
Project (HCUP), National Program of Cancer Registries (NPCR), and Surveillance, 
Epidemiology and End Results (SEER) databases were analyzed. Based on AHRQ’s 
Prevention Quality Indicators, preventable hospitalizations related to diabetes, 
hypertension, asthma, chronic obstructive pulmonary disease, and congestive 
heart failure (CHF) were analyzed. In addition, we examined incidence of 
preventable cancers (cervical and colon). Data from 2005 were compared to 
2009/2010 data; changes were examined both in Massachusetts and compared to 
national trends. RESULTS: The proportion of uninsured patients in 
Massachusetts decreased in 2010 compared to 2005 across all 5 categories of 
preventable hospitalizations. In Massachusetts, preventable discharges 
decreased only for diabetes and CHF. While the magnitude of decrease was 
greater in diabetes (-0.02% Massachusetts vs. -0.004% nationally), this trend was 
reversed in CHF (-0.17% vs. -0.31%). Results were similarly mixed across the 
remaining preventable hospital conditions. SEER data indicate that incidence of 
cervical and colon cancer decreased in both Massachusetts (-3.2/100,000 and  
-5.4/100,000 for cervical and colon cancer, respectively) and nationally  
(-1.2/100,000 and -3.6/100,000) from 2005-2009: the magnitude of decrease was 
larger in Massachusetts. Similar trends in colon cancer were found in NPCR data: 
incidence of colon cancer declined by 10.4/100,000 patients in Massachusetts 
compared with 6.9/100,000 nationally. CONCLUSIONS: Massachusetts health 
care reform has increased insurance coverage, though its impact on patient 
outcomes is less clear. As similar national legislation is implemented, research is 
needed to determine whether and how increased insurance coverage can be 
linked to improved patient outcomes.  
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OBJECTIVES: This study assesses the financial impact of Patient Protection and 
Affordable Care Act (PPACA) regulations on the pharmaceutical industry. 
METHODS: U.S. Public Law was searched from 2007 - 2012 to identify profit-
impacting regulatory changes on pharmaceutical and biotechnology 
manufacturers. Relevant results were then juxtaposed against aggregated and 
standardized Medicaid General Ledger accounts. A simple predictive model was 
built to examine the relationship. RESULTS: Public Law 111-148, Sec. 2501 
PRESCRIPTION DRUG REBATES indicated a change, effective as of March 23, 2010, 
increasing the minimum Medicaid Drug Rebate from 15.1% to 23.1% of the 
Average Manufacturer Price (AMP). The AMP is calculated as an aggregated 
average of all commercial sales transactions to and through retail community 
pharmacies. By modelling the top 100 manufacturers' average profit measures, it 
is estimated that the industry, on average, stood to lose a minimum of 8% in 
profitability in the Medicaid market segment. The Medicaid market segment 
comprises approximately 20% of all U.S. manufacturer sales, suggesting the 
PPACA could have a considerable impact on pharmaceutical profits overall. 
CONCLUSIONS: Basic statistical methods suggest that PPACA regulations may 
directly impact pharmaceutical company profits. Given the significant 
consolidation, acquisition, divestiture, and reorganization activities during this 
time period, it is possible that these regulations are indirectly reshaping the 
pharmaceutical industry landscape. Regression analyses should be conducted to 
analyze the link between the Medicaid rebate increases with manufacturer 
organizational change and subsequent business outcomes.  
 
PP3  
TRANSFORMATION OF SERVICES AND CARE PATHWAY REDESIGN IN THE NHS: 
FURTHER REFORMS IN HEALTH POLICY  
Mallinson M, King P 
Access Partnership, London, UK  
OBJECTIVES: The NHS is meeting efficiency savings through 4 areas: quality, 
innovation, productivity & prevention (QIPP). There is currently a considerable 
degree of uncertainty from the Department of Health (DH) as to whether the 
demand for health care is being managed in ways that inappropriately restricts 
patients’ access to care. Reducing demand and redesigning care pathways to 
treat patients in the most appropriate setting are key ways of generating savings. 
However transforming services within a prospective payment driven systems is 
fraught with difficulty. A review was undertaken of current Health Policies and 
Independent Government office findings e.g. National Audit Office (NAO) as to 
the likely reality of achieving efficiency saving via this route. METHODS: A 
survey of PCT clusters and NAO findings was undertaken to understand how 
these policy initiatives were being introduced and to understand the barriers to 
services transformation. RESULTS: In 2011-12 47% of PCT clusters reinvested less 
than a quarter of their cash releasing savings in transforming services. The 
perceived barriers to services transformation were perceived as; Lack of 
measures to invest first e.g. in community services; organizational barriers 
between health & social care including information sharing and differing 
financial priorities; lack of influence over acute providers; organizational barriers 
between acute and community services; some transformations would be better 
enforced at a regional or national level; staff across patient care pathways do not 
have the right skills; lack of evidence to convince stakeholders of the benefits of 
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service transformation. CONCLUSIONS: Currently financial incentives do not 
always encourage providers to transform services or to work collaboratively with 
each other or with commissioners of care.  
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OBJECTIVES: To examine whether utilization of antidepressants by dual eligibles 
were different under Part D compared to Medicaid period by focusing on states 
which vary baseline state Medicaid policies and wrap-around programs for  
dual eligibles to access drugs under Part D. METHODS: A pre-post study design 
with a longitudinal dataset by linking Medicaid data for 2004-2005 and 5% 
random sample of Medicare data for 2006-2007. The study population is dual 
eligibles, existing users of antidepressants in 2004 and with enrollment from 
2004-2007 in eight states. We employ a state-fixed effect model to estimate 
medication utilization using proportion of days covered (PDC), adjusting for 
beneficiaries characteristics and health status. We adopt generalized estimation 
equation (GEE) model for estimation and spline regression for investigating 
whether changes in PDCs is related to Part D. A stratified analysis is conducted 
for community based dual eligibles (n=4,703) and nursing home dual eligibles 
(n=1,504) separately. RESULTS: Adjusted PDCs increased to 4.25 percentage  
point among community dual eligibles (p=0.00) but did not change among 
nursing home dual eligibles (p=.74) under Part D. Adjusted changes in PDCs  
were not significant for most states, except Arkansas community based dual 
eligibles (p=0.00), Florida nursing home dual eligibles (p=0.03) and New Mexico 
nursing home dual eligibles (p=0.01), which had significant increases under  
Part D. Separate spline regression for these states indicated that trends in  
PDC before and after Part D were not significantly different, suggesting  
that changes were not related to transition to Part D. CONCLUSIONS: We did not 
find empirical support for concerns regarding disruption of medication 
utilization of the dual eligible under Part D. Although states had different 
baseline Medicaid polices and wrap-around programs under Part D, lack of 
significant changes in utilization suggest that minor changes in copayments and 
refill/prescription limits etc. do not have large effect on medication utilization to 
antidepressants.  
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OF THREE INPATIENT TREATMENT ALTERNATIVES IN THE  
UNITED STATES  
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OBJECTIVES: Heart failure (HF) is the most frequent cause of hospitalization 
among US elderly. Despite limited evidence, current guidelines recommend the 
use of IV vasodilators in addition to IV loop diuretics (LD) for the treatment of 
acute HF (AHF) patients without hypotension. We investigated whether elderly 
patients hospitalized for AHF treated with IV LD combined with IV nitrates (NT) 
or IV nesiritide (NES) achieved better outcomes compared to those receiving IV-
LD alone. METHODS: US hospital billing records (2007-2009) from the MarketScan 
Hospital Drug Database were analyzed. Patients ≥65 years old, with an AHF 
diagnosis and no evidence of hypotension and/or cardiogenic shock were 
included. Patients receiving IV-LD alone were paired with patients receiving IV-
LD+NT and with patients receiving IV-LD+NES using propensity score matching. 
Outcomes included in-hospital mortality, length of stay (LOS), cost, and HF re-
hospitalization rate. RESULTS: Compared to IV-LD alone (N=2,918), patients 
receiving IV-LD+NT (N=2,918; mean age 78.5 years, 44.7% male) had longer LOS 
(days, ICU: 1.5 vs. 2.2; total: 5.8 vs. 7.1, p<0.01 for both), higher costs ($8,810 vs. 
$13,387, p<0.01), but similar rates of mortality (2.2% vs. 2.5%, p>0.05) and one 
year HF re-hospitalization (37.2% vs. 37.4%, p>0.05). Compared to IV-LD alone 
(N=1,561), patients receiving IV-LD+NES (N=1,561; mean age 77.8 years, 56.7% 
male) had longer LOS (days, ICU: 1.9 vs. 2.4; total: 5.9 vs. 7.8, p<0.01 for both), 
higher costs ($8,775 vs. $13,040, p<0.01), higher one year HF re-hospitalization 
rates (38.2% vs. 41.8%, p<0.05), but similar mortality rates (2.8% vs. 3.5%, p>0.05). 
CONCLUSIONS: This study amongst elderly AHF patients indicates that neither 
NT nor NES in addition to diuretics improve survival compared to diuretics 
alone, and are associated with longer LOS and higher hospitalization costs. 
These results raise the question as to whether currently utilized IV vasodilators 
are of value in the treatment of elderly AHF patients.  
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OBJECTIVES: Consumer-Driven and High Deductible Health Plans (CDHP/HDHP) 
are becoming more common in employer-sponsored plans. Approximately 60% 
of large firms offered a CDHP/HDHP in 2011. In this study we estimate the short- 
and long-term impact of enrollment in a CDHP/HDHP on use of chronic 
medications for diabetes and cardiovascular disorders. METHODS: A total of 
524,043 CDHP/HDHP enrollees age 18-64 were propensity score matched to a 
comparison group within similar firms not offering CDHP/HDHP (total 
n=1,048,086). A quarterly cross-section time series dataset was created for 
enrollees one year before and up to four years after enrollment in a CDHP/HDHP. 
The impact of CDHP/HDHP was evaluated using difference-in-differences, 
reported as a percent change in trend relative to the comparison group. 
Medication use outcomes included percent of days covered (PDC) and percent 
adherent (PDC>80%) for the following drug classes: diabetes, hypertension, 
dyslipidemia, and other cardiovascular medications, overall and for brand and 
generic drugs. Administrative claims data was obtained from the MarketScan 
Commercial Claims and Encounters Database, 2006-2010. RESULTS: One year 
after enrollment, the trend in PDC for oral diabetes medications in the 
CDHP/HDHP was 4.1% lower than the trend in the comparison group (p<0.001). In 
addition, the one-year trend in PDC for brand name oral diabetes medications 
was 10.8% lower than the comparison group (p<0.001). CDHP/HDHP enrollees 
experienced lower levels of adherence to all other drug classes within 1 year of 
enrollment. The negative impact of CDHP/HDHP on PDC grew over time. For 
example, the trend in PDC for oral diabetes medications was 34.2% lower for 
CDHP/HDHP enrollees than the comparison group (p<0.01) after four years of 
enrollment in a CDHP/HDHP. CONCLUSIONS: Enrollment in a CDHP/HDHP is 
associated with lower use of and adherence to medications for chronic 
conditions, potentially exacerbating these chronic conditions.  
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OBJECTIVES: Overweight and obesity are a growing epidemic in the US, affecting 
more than two-thirds of working-age adults. This study quantifies the economic 
burden associated with obesity from the employer’s perspective, including 
employee medical, drug, sick leave (SL), short- and long-term disability (STD; 
LTD), and workers’ compensation (WC) costs, work absence days, and self-
reported productivity. METHODS: Using a retrospective database from large 
employers throughout the US, employees’ body mass index (BMI) values (widely 
used for categorizing obesity) from 2003-2011 health risk appraisal data were 
used to create 3 cohorts: BMI<27, 27<=BMI<30, and BMI>=30. All employees were 
required to have at least 12 months of health coverage post-index (first BMI 
measurement). Medical and drug costs, SL, STD, LTD, and WC costs and absence 
days, and Health Productivity Questionnaire responses were measured 12 
months post-index and compared between cohorts using regression modeling. 
Models controlled for differences between cohorts in age, gender, marital status, 
race, salary, zip-code region, and index year. Employees with pregnancy medical 
claims were excluded. RESULTS: The study included 39,696 (BMI<27), 14,281 
(27<=BMI<30), and 18,801 (BMI>=30) eligible employees. Average age and annual 
salary were 38.8 years and $87,604 (BMI<27), 40.9 and $83,178 (27<=BMI<30), and 
40.9 and $65,843 (BMI>=30), respectively. Females represented 32.8% (BMI<27), 
22.9% (27<=BMI<30), and 38.9% (BMI>=30) of employees. Per-employee adjusted 
total annual costs (medical, drug, SL, STD, LTD, and WC combined) were $4,258 
(BMI<27), $4,873 (27<=BMI<30), and $6,313 (BMI>=30). Medical and drug costs and 
SL and WC costs and days were significantly higher for higher BMI cohorts 
(P<0.01). The BMI>=30 cohort had significantly more STD costs and days and 
lower productivity than other cohorts (P<0.001). CONCLUSIONS: Employees with 
higher BMI levels are associated with significantly more costs, more absence 
from work, and lower self-reported productivity, representing a significant 
economic burden for US employers considering the high prevalence of 
overweight and obesity.  
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THE ASSOCIATION OF BURN INJURIES AND PSEUDOEPHEDRINE  
SALES  
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University of Kentucky, Lexington, KY, USA  
OBJECTIVES: Pseudoephedrine (PSE) is used as a precursor in the illicit 
production of methamphetamine. Policies that restrict the sales of PSE have 
been adopted to curb production, which causes chemical and thermal burn 
injuries that create cost and treatment burdens on the health care system. The 
purpose of this project is to estimate the relationship between burn injuries and 
PSE sales. METHODS: PSE sales data from the National Precursor Log Exchange 
were merged with hospital discharge data from the Kentucky Cabinet for Health 
and Family Services Office of Health Policy Public Use Data Set. Kentucky 
residents with a primary diagnosis of burn (ICD-9 940.0-949.5) in 2010 were 
included. A negative binomial regression was performed with number of burns 
per county as the dependent variable. The primary explanatory variable was PSE 
sales per county (in grams/100 residents). Control variables included: % high 
school graduates over 25, urbanicity, and unemployment, all adjusted by county 
population. RESULTS: In 2010, 340 burns were treated in Kentucky facilities with 
33 counties having no burns and 94% of counties having 6 or fewer burns. Mean 
PSE sales were 49 g/100 county residents (SD=39), with a range of 0.3 g to 147 g 
per 100 county residents. A 1 gram increase in PSE sales per 100 residents was 
associated with an increase of approximately 1.1 burns per county (p<0.001). 
Controlling for population, urban counties had more burns than rural counties 
(p=0.004) and counties with higher percentages of high school graduates had 
fewer burns (p<0.001). Results were robust to various dispersion settings. 
CONCLUSIONS: These results suggest that PSE sales are associated with burn 
injuries. Limitations include missing data on cross-border PSE sales and the 
inability to distinguish methamphetamine-related burn injuries from other 
burns. These findings suggest that additional PSE sales restrictions may reduce 
the number of burn-related discharges.  
